Answers are grounded in this paper and cite their sources.
The first rotavirus vaccine now has been licensed by the Food and Drug Administration. In the course of reviewing information on adverse events from clinical trials of live attenuated rhesus-human reassortant rotavirus vaccines administered orally, we identified 5 cases of intussusception among ∼10 000 vaccine recipients but only 1 among 4600 controls. Because viral enteric infection has been implicated as an inciting event for intussusception, our observation raised the question of whether the association with rotavirus vaccination was a causal association or the result of chance alone. To address this concern we compared the age occurrence and rates of intussusception among children participating in the rhesus rotavirus vaccine trials with other populations of children of similar ages. Additionally the seasonal distributions of hospitalizations for intussusception and for rotavirus gastroenteritis were reviewed from hospital discharge data to determine whether the 2 diseases temporally coincided. Methods.Study populations. All hospitalizations of children participating in 11 trials of Wyeth-Ayerst Laboratories rotavirus vaccine candidates were reviewed for cases of intussusception to compare the rates of intussusception between recipients of vaccine and of placebo. Additionally hospitalizations with rotavirus diarrhea [International Classification of Diseases1 (ICD) 9-CM Code 008.61] or intussusception (ICD9-CM Code 560) listed for children <5 years of age were obtained with the use of data from the New York Statewide Planning and Research Cooperative System from 1991 through 1995 and from the Kaiser Permanente Medical Care Program of Northern California for 1995 and 1996. Census data for New York State in 1993 (New York Department of Health, Bureau of Biometrics, March, 1995) and from Northern California Kaiser-Permanente for 1995 and 1996 were used to determine intussusception rates for these populations. Additionally the seasonal distributions of hospital discharges for rotavirus and for intussusception among New York State children ages 3 through 23 months were examined. Vaccinations. Children in the Wyeth-Ayerst rotavirus vaccine trials received either tetravalent rhesus-human reassortant rotavirus vaccine containing G serotypes 1, 2, 3 and 4 or a monovalent serotype 1 vaccine. The studies were approved by the Institutional Review Board for each site, and written informed consent was obtained from a parent or legal guardian. Included in this evaluation are studies of three dosage levels of vaccine, two vaccine formulations and two buffering methods. The trials conducted were safety and immunogenicity studies in which children were followed through age 7 months or efficacy trials in which children were monitored until ∼12 to 24 months of age. Statistical method. Rates of intussusception in the vaccine and placebo recipients participating in rotavirus vaccine trials were compared by using the Poisson regression analysis.2 Results.Rates of intussusception among participants in vaccine trials and in background populations. Intussusception occurred during the first 12 months of life in 1 of 4633 placebo recipients (0.022%) vs. 5 of 10 054 (0.05%) of all rotavirus vaccinees, which included 2 of 8240 (0.024%) given the tetravalent rotavirus vaccine at the dosage proposed for licensure. These differences were not significant by Poisson regression analysis, P = 0.45 and 0.92, respectively. Also the proportions of vaccinees with intussusception appear to be similar to those seen in background populations: Northern California Kaiser Permanente in 1995 through 1996, 37 of 49 999 (0.074%); New York State from 1991 through 1995, 136 of 269 832 annually (0.05%). Age distribution of intussusception among vaccinees and background populations. The cases of intussusception identified among recipients of rotavirus vaccine occurred between Days 6 and 51 after the second or third dose of vaccine, at which time recipients were age 4 through 7 months. The number of hospitalizations in New York State by month of age demonstrates that most cases of intussusception occur during the first year of life and are most frequent in children 4 through 9 months of age (Fig. 1).Fig. 1: Number of hospitalizations for intussusception by month of age in New York State, 1991 to 1995.Seasonal distribution of intussusception and rotavirus. For New York State we plotted the monthly percentage of total hospitalizations for rotavirus gastroenteritis and for intussusception for children ages 3 through 23 months during the 3-year period 1993 to 1995 (Fig. 2). Rotavirus disease peaked in late winter and early spring, whereas intussusception hospitalizations were fairly evenly distributed throughout the year, indicating no obvious association.Fig. 2: Seasonal distribution of hospitalizations for rotavirus diarrhea and for intussusception among children ages 3 to 23 months in New York State, 1993 to 1995.Discussion. The occurrence of intussusception among five children given rotavirus vaccine raised the concern that if the relationship is causal, many cases might emerge with widespread use of the vaccine. Alternatively natural cases might diminish from introduction of an effective rotavirus vaccine. Several observations from our examination of hospital discharge data speak against such a causal relationship: (1) in New York State the winter peaks of hospitalization for rotavirus were not matched for intussusception, which occurs year-round; (2) if such a relationship existed we might expect to find an increased number of cases of intussusception after the first rotavirus vaccination, when most children are infected by the vaccine strains. Instead all five instances of postvaccination intussusception occurred after the second or third dose among children ages 4 to 7 months, the age group at highest risk for intussusception; and (3) the difference in rates of intussusception are not significantly different between recipients of vaccine or placebo or between vaccinees and residents of New York State or enrollees of Kaiser Permanente of Northern, suggesting no increased rates of intussusception after rotavirus vaccination. Because it is biologically plausible that rotavirus infection could cause hypertrophy of intestinal lymphoid tissue leading to intussusception, studies have been performed previously to search for this relationship. These studies have been uncontrolled and have yielded conflicting results. In 1978 Konno et al.3 reported detecting rotavirus by electron microscopy in the stools of 11 of 30 infants and young children with intussusception, suggesting that rotavirus was a cause of intussusception. A French study of 64 children with intussusception concluded that rotavirus was not the etiologic agent of intussusception.4 Six of their children had antibody rises to rotavirus, but 4 had an adenovirus infection and a fifth case likely represented nosocomial rotavirus infection in a child hospitalized for intussusception. In Australia Mulcahy et al.5 prospectively found no evidence of rotavirus infection in 22 of 24 children with acute intussusception, and the retrospective portion of their study failed to demonstrate the seasonal variation in the occurrence of intussusception that was seen for rotavirus. In summary past studies have not proved that rotavirus causes intussusception, and all lines of evidence in our study failed to demonstrate an etiologic association between natural or vaccine rotavirus infection and intussusception. Implementation of a rotavirus vaccination program therefore would not be expected to result in either an increase or a decrease in intussusception rates. However, as with all new vaccines, postvaccination surveillance for occurrence of rare side effects is important. Margaret B. Rennels, M.D. Umesh D. Parashar, M.B.B.S, M.P.H. Robert C. Holman, M.S. Chinh T. Le, M.D. Hwa-Gan Chang, M.P.H. Roger I. Glass, M.D., Ph.D. Department of Pediatrics and Center for Vaccine Development; University of Maryland School of Medicine; Baltimore, MD (MBR) Viral Gastroenteritis Section; Respiratory and Enteric Viruses Branch (UDP, RIG); Office of the Director; Division of Viral and Rickettsial Diseases; National Center for Infectious Diseases (RCH); Epidemic Intelligence Service; Epidemiology Program Office; Centers for Disease Control and Prevention; Public Health Service; US Department of Health and Human Services (UDP); Atlanta, GA Kaiser Permanente Medical Care Program of Northern California; Oakland, CA (CTL); New York State Department of Health; Albany, NY (HC)
No takes yet. Share an insight, caveat, or question.
Rennels et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: